---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007945"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:46:07.423177+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# InfuSystem FY2022 revenue up 7% to record $109.9M, but adjusted EBITDA down 14%

## Summary
- Full year net revenue $109.9M (+7% YoY); Q4 revenue $28.8M (+9% YoY).
- Adjusted EBITDA $20.7M FY2022, down 14% YoY; Q4 adj. EBITDA $5.5M, down 16%.
- Net income for year less than $0.1M; Q4 diluted EPS $0.01.
- Guides FY2023 revenue growth 8-10% (~$118-121M); adj. EBITDA margin >19%.
- Launched wound care JV with Sanara Medtech; biomedical services contract ramp-up continues.

## SEC filing metadata
- accession: 0001628280-23-007945
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/0001628280-23-007945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/infu-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007945
- JSON: https://secwatch.observer/filing/0001628280-23-007945.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007945.txt

## Key facts
- Earnings Releases
  InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2022 results: revenue Net revenues totaled $109.9 million, net income Net income of less than $0.1 million, EPS $0.01 per diluted share. Guidance reaffirmed.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: Net revenues totaled $109.9 million
  - Net income: Net income of less than $0.1 million
  - EPS: $0.01 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/0001628280-23-007945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.